MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/cas.16198

Медицинская библиотека · Cancer science · 2024

The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation.

Shimazu Yutaka, Kanda Junya, Suzuki Kazuhito, Wada Akinori, Kikuchi Taku, Ikeda Takashi, Tsukada Nobuhiro, Miwa Akiyoshi, Itagaki Mitsuhiro, Kako Shinichi, Nishiwaki Kaichi, Ota Shuichi, Fujiwara Shin-Ichiro, Kataoka Keisuke, Doki Noriko, Sawa Masashi, Hiramoto Nobuhiro, Nishikawa Akinori, Imai Toshi, Ichinohe Tatsuo, Kanda Yoshinobu, Atsuta Yoshiko, Kawamura Koji

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

The anti-CD38 antibody daratumumab (Dara) has been reported to improve the prognosis of multiple myeloma (MM) patients, but its use before autologous stem cell transplantation (ASCT) remains controversial. To clarify the prognostic impact of Dara before ASCT on MM, we performed a retrospective observational analysis. We analyzed 2626 patients who underwent ASCT between 2017 and 2020. In the comparison between patients not administered Dara (Dara- group) and those administered Dara (Dara+ group), the 1-year progression-free survival (PFS) rates were 87.4% and 77.3% and the 1-year overall survival (OS) rates were 96.7% and 90.0%, respectively. In multivariate analysis, age <65 years (p = 0.015), low international staging system (ISS) stage (p < 0.001), absence of unfavorable cytogenic abnormalities (p < 0.001), no Dara use before ASCT (p = 0.037), and good treatment response before ASCT (p < 0.001) were independently associated with superior PFS. In matched pair analysis, the PFS/OS of the Dara- group were also significantly superior. For MM patients who achieved complete or very good partial response (CR/VGPR) by Dara addition before ASCT, both PFS and OS significantly improved. However, in patients who did not achieve CR/VGPR before ASCT, the PFS/OS of the Dara+ group were significantly inferior to those of the Dara- group.

Для цитирования: Shimazu Yutaka, Kanda Junya, Suzuki Kazuhito, Wada Akinori, Kikuchi Taku, Ikeda Takashi, Tsukada Nobuhiro, Miwa Akiyoshi, Itagaki Mitsuhiro, Kako Shinichi, Nishiwaki Kaichi, Ota Shuichi, Fujiwara Shin-Ichiro, Kataoka Keisuke, Doki Noriko, Sawa Masashi, Hiramoto Nobuhiro, Nishikawa Akinori, Imai Toshi, Ichinohe Tatsuo, Kanda Yoshinobu, Atsuta Yoshiko, Kawamura Koji. The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation.. Cancer science. 2024. DOI: 10.1111/cas.16198.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.